To the Editor: Sheremata et al. (June 8 issue)1 reported severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b in a patient with multiple sclerosis. They indicated that it was a new complication of treatment with interferon beta-1b, which had not been observed with natural or recombinant interferon alfa. However, we described a case of cutaneous necrosis caused by the injection of interferon alfa in a patient with chronic myelogenous leukemia.2 Cutaneous necrosis due to interferon alfa was also reported by Cnudde et al.3 and subsequently by Orlow and Friedman-Kien4 in patients with Kaposi's sarcoma related to the acquired immunodeficiency.
ASJC Scopus subject areas